Tweetable abstract Semi-depot house dust mite allergen extract is safe and well tolerated in children and adolescents with allergic rhinitis and asthma. Aim: Multicenter study to investigate the safety of mite extract product Novo-Helisen Depot, Strengths 1 to 3 (NHD3), as subcutaneous immunotherapy (SCIT), in Chinese children and adolescents with allergic rhinitis (AR) and allergic asthma (AA). Patients & methods: We evaluated SCIT-related adverse events (AEs) during NHD3 14-week initial therapy in children (5-11 years) and adolescents (12-17 years) with perennial symptomatic AR and AA. Results: Among 3600 injections in 250 patients, 361/3600 (10.0%) injections caused SCIT-related AEs in 96/250 (38.4%) patients, 321/3600 injections (8.9%) caused local reactions in 89/250 (35.6%) and 40/3600 injections (1.1%) caused systemic reactions in 23/250 (9.2%). Conclusion: Initial SCIT treatment using NHD3 was safe and well tolerated in Chinese children and adolescents with AR and AA.
基金:
Merck Serono China Co. Ltd, an affiliate of Merck KGaA, Darmstadt, Germany
第一作者单位:[1]Beijing Childrens Hosp, Dept Allergy, Beijing 100045, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Xiang Li,Liu Fengxia,Zhi Lili,et al.Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma[J].IMMUNOTHERAPY.2021,13(3):227-239.doi:10.2217/imt-2020-0232.
APA:
Xiang, Li,Liu, Fengxia,Zhi, Lili,Jiang, Weihong,Liu, Changshan...&Chang, Peter.(2021).Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma.IMMUNOTHERAPY,13,(3)
MLA:
Xiang, Li,et al."Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma".IMMUNOTHERAPY 13..3(2021):227-239